CN102335176A

CN102335176A - Brand-new oral solid medicinal composition and preparation method thereof

Info

Publication number: CN102335176A
Application number: CN2011101972806A
Authority: CN
Inventors: 马鹰军; 钟正明; 王小树; 罗韬
Original assignee: HAINAN JINRUI PHARMACEUTICAL CO Ltd
Current assignee: HAINAN JINRUI PHARMACEUTICAL CO Ltd
Priority date: 2011-07-14
Filing date: 2011-07-14
Publication date: 2012-02-01
Anticipated expiration: 2031-07-14
Also published as: CN102335176B

Abstract

The invention discloses a brand-new oral solid medicinal composition. The medicinal composition is an oral preparation prepared from hydrochlorothiazide, levamlodipine, valsartan and pharmaceutically acceptable auxiliaries, and the oral preparation comprises but is not limited to tablets or capsules. The composition comprises the following raw materials in parts by weight: 5-25 parts of the hydrochlorothiazide, 2.5-5 parts of the levamlodipine, 80-160 parts of the valsartan, 40-120 parts of microcrystalline cellulose, 30-90 parts of compressible starch, 5-25 parts of cross-linked sodium carboxymethylcellulose, 3-8 parts of silicon dioxide and 1-2 parts of stearic acid. The medicinal composition disclosed by the invention has the advantages of scientific and reasonable prescription, low auxiliary content and high bioavailability, and is a first choice of medicine for treating hypertension.

Description

The medicinal composition and method of making the same of a kind of brand-new oral administration solid

Technical field

The invention belongs to medical technical field, be specifically related to a kind of medicinal composition and method of making the same of brand-new oral administration solid that comprises hydrochlorothiazide, valsartan and Levamlodipine.

Background technology

Hypertension is modal cardiovascular disease, is the great public health difficult problem in the global range.China 1991 has carried out sample census to 940,000 crowds more than 15 years old, and statistics shows: China's hypertension prevalence has reached 11.26%, and than increasing 25% in the period of the 1979-1990 10, the existing hyperpietic of China surpasses 1.3 hundred million.And the impetus of this rising is still continuing.Statistics shows that also hypertension therapeutic rate city is 17.4%, and the rural area is 5.4%; Control rate (through treatment systolic pressure＜140mmHg, diastolic pressure＜90mmHg) only 2.9%.Can find out that from above-mentioned statistics China's hypertension prevalence constantly increases, but treatment rate, control rate are low, form huge contrast.According to the WHO prediction, will account for 79% of China's cause of death to the year two thousand twenty noninfectious, wherein the cardiovascular diseases will account for the first place.In order to contain the arrival on this cardiovascular diseases peak, carry out the control of hypertension energetically, the active treatment hyperpietic, very urgent.

The bad hypertension of long-term control can produce grievous injury to target organs such as the heart, brain, kidneys; Actively main cardiovascular diseases's M & M can be significantly lowered in the blood pressure lowering treatment, and most hypertensive patients need use the depressor could be with controlling of blood pressure in ideal target blood pressure level.The evidence-based medicine EBM evidence shows, low dose of Combined application variety classes antihypertensive drugs is better and untoward reaction is less with heavy dose of a certain medicine antihypertensive effect than single.Therapeutic alliance can improve efficacy of antihypertensive treatment, in the untoward reaction that causes with different pharmaceutical, blood pressure reduces the compensation response that triggers when preventing single therapy, increases patient's toleration, improves compliance.

Levamlodipine belongs to long-acting dihydropyridine (DHP) type calcium antagonists; On the amlodipine basis, split out; Its drug effect is 2 times of racemic amlodipine, and Levamlodipine has the effect of protection EH patient renal function, not only depends on the decline of system's blood pressure.Also because the afferent glomerular arteriole of nephrectasia bead lastingly of this medicine; Improve the kidney ischemia, stop the disorder of kidney blood vessel and glomerule 26S Proteasome Structure and Function, alleviate the kidney hypertrophy; Reducing mesenteric tissue catches macromolecular substances; Suppress free radical and form, weaken the somatomedin mitosis reaction, improve the mitochondrial calcium load and reduce the nephron metabolism all useful kidney.Levamlodipine possess onset slowly, long action time, characteristics that the paddy p-ratio is high, the clinical treatment that has been widely used in cardiovascular and cerebrovascular diseases such as hypertension, angina pectoris.Levamlodipine can change the VSMC calcium ion and stride the film transfer, reduces flow of calcium ions, makes cardiac muscle and vascular smooth muscle relaxation; Regulate the picked-up of vascular endothelial cell, smooth muscle cell and macrophage to lipoprotein; Regulate cellular cholesterol for body, reduce the deposition of cholesterol, suppress the short vascular smooth muscle hypertrophy of somatomedin at arterial wall; The mononuclear cell that slows down is invaded profit and platelet aggregation; Increase erythrocyte deformability, blood viscosity lowering delays atherosclerotic formation and development.Levamlodipine mainly acts on all blood vessels; Also can act on coronary artery and renal artery, slow with the acceptor site effect, vasorelaxation action is steady; Conducting system of heart and myocardial contraction all there is not the obvious suppression effect; Can reduce cardiac load, reverse ventricular hypertrophy, and blood glucose, blood fat and serum electrolyte are had no adverse effects.

Levamlodipine is a calcium channel blocker of new generation, clinical treatment hypertension, angina pectoris and the correction Atheromatosis reason state of being mainly used in.Dihydropyridine calcium channel blocker is one of the most frequently used clinically cardiovascular drugs, is widely used in the treatment of cardiovascular disease such as hypertension, angina pectoris and arrhythmia.Along with the research to dihydropyridine calcium channel blocker deepens continuously, find that all dihydropyridine calcium channel blockers all have chiral structure except that nifedipine, and its enantiomer biological activity is usually different in recent years, in addition opposite.Amlodipine (amlodipine) is clinical dihydropyridine calcium channel blocker commonly used, has left-handed and two kinds of enantiomer of dextrorotation.Levamlodipine is the renewal product of amlodipine, obtains through chiral separation technology, and is nontoxic and hypotensive effect arranged, and R toxicity is big and do not have a hypotensive effect.Therefore, Levamlodipine maybe be more effective than amlodipine, and safety is higher.Levamlodipine possess onset slowly, long action time, characteristics that the paddy p-ratio is high, the clinical treatment that has been widely used in cardiovascular and cerebrovascular diseases such as hypertension, angina pectoris.

The benzenesulfonic acid Levamlodipine Besylate, chemical name: (s) (-) 3-ethyl-5-methyl-2-(2-ammonia ethoxymethyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridine dicarboxylate benzene sulfonate.Molecular formula: C20H25N2O5ClC6H6O3S, molecular weight: 567.1.

Valsartan, chemical name: (S)-N-valeryl-N-{ [2 '-(1H-tetrazole-5-yl) [1,1 '-biphenyl]-4-yl] methyl }-valine, molecular formula: C ₂₄H ₂₉N ₅O ₃, molecular weight: 435.53.

Valsartan is a kind of Angiotensin (ARB) of non-peptide class, has effects such as blood pressure lowering, expansion blood vessel, can be used for preventing and treating cardiovascular system diseases such as hypertension, coronary heart disease, heart failure.After succeeding in developing by Switzerland Novartis Co.,Ltd, at first go on the market in Germany.In December, 1996 obtains drugs approved by FDA, and commodity were called " Diovan " in U.S.'s listing in 1997, and the valsartan of Novartis Co.,Ltd in 1998 obtains registration in China, and commodity are called " DAIWEN ".After the valsartan listing, Novartis Co.,Ltd has developed diovan compound preparation again.After the valsartan and Hydrochlorothiade compound preparation is succeeded in developing, obtain FDA approval listing in October, 1997, and commodity are called " CoDiovan " (multiple DAIWEN); 2006, valsartan newly developed/amlodipine compound preparation was also got permission listing.

Valsartan has the advantage of angiotensin AT1 receptor antagonist of new generation; Compare with angiotensin converting enzyme inhibitor (ACEI) medicine; It directly acts on the AT1 receptor competitively, makes vascular smooth muscle relaxation, vasodilation, improves ventricle and blood vessel is reinvented; Simultaneously can improve kidney blood perfusion amount, increase water, sodium excretion, reduce blood volume, and make blood pressure drops; Hypotensive effect is reliable, safety, side effect are little; Simultaneously obtain the treatment that drugs approved by FDA is used for heart failure, can significantly reduce multiple risk factor such as patients with atrial fibrillation heart failure incidence rate and cardiovascular and cerebrovascular vessel incident.The different mechanisms that compound preparation can be brought into play medicine produces synergism, under the situation that dosage reduces, makes blood pressure up to standard, improves patient's arterial compliance and the untoward reaction that reduces single dose simultaneously.

Hydrochlorothiazide is the diuretic that acts on tubular distal of extensive use clinically; Mechanism of action mainly suppresses the heavily absorption to sodium chloride of distal tubule leading portion and proximal tubule (acting on lighter); Thereby increase the Na+-K+ exchange of distal tubule and collecting tubule, the K+ secretion increasing.Except that the effect of diuresis row sodium, also have the outer mechanism of action of kidney to participate in blood pressure lowering.Be applicable to edema and hypertensive treatment, can effectively control moderate hypertension, adverse reaction rate is low.

Utilize calcium channel blocker amlodipine, ARB valsartan and diuretic hydrochlorothiazide, process compound preparation, give full play to three's complementation, synergism, help to control better patient's blood pressure.

Medical evidence shows, low dose of Combined application variety classes antihypertensive drugs is better and untoward reaction is less with heavy dose of a certain medicine antihypertensive effect than single.Therapeutic alliance can improve efficacy of antihypertensive treatment, in the untoward reaction that causes with different pharmaceutical, blood pressure reduces the compensation response that triggers when preventing single therapy, increases patient's toleration, improves compliance.

Amlodipine (amlodipine) or its salt are dihydropyridine calcium channel blocker of new generation (CCB) like Amlodipine Besylate Tablet; And valsartan (valsartan) is a kind of angiotensin receptor blocker (ARB).Both all have effects such as blood pressure lowering, expansion blood vessel, can be used for preventing and treating cardiovascular system diseases such as hypertension, coronary heart disease, heart failure.

Existing research shows that CCB and ARB share can have certain synergism, discloses the compound antihypertensive drug of a kind of amlodipine and irbesartan like patent documentation CNZL03150996.7; CN1765362A discloses a kind of compositions that comprises amlodipine and angiotensin ii receptor antagonist (ARB), and the weight proportion of wherein having mentioned amlodipine and candesartan Cilexetil is 1: 10-10: 1; WO2006/034631 discloses the compositions of a kind of amlodipine and ARB; CN200610081591.5 discloses a kind of pharmaceutical composition that comprises the treatment hypertension and cardiovascular disease of Levamlodipine officinal salt and ARB.

Wang Xiaolin reports (pharmacological action of Levamlodipine and clinical practice; Shandong medicine thing Qilu Pharmacential Affairs 2010 Vol.29; No.10) Levamlodipine is the more outstanding calcium channel blocker that goes on the market at present; As a line medication of common treatment cardiovascular disease, advantage such as have and untoward reaction is few long-acting, efficient.Levamlodipine can reduce peripheral vascular resistance, has antiplatelet aggregation, prevents that atherosclerosis from forming, and the protection tunica intima is improved pharmacological actions such as myocardial oxygen delivery.In recent years, many these article of discovering are brought into play the positive therapeutic effect in multiple cardiovascular disease, along with the research to the darker people of its mechanism of action, will excavate out more wide application prospect.

People such as Fan Shougen to valsartan and Levamlodipine coupling to the senile hypertension patient urinate micro-albuminised influence (; Chongqing medical science the 39th the 8th phase of volume of April in 2010) studies, reach a conclusion: the hypotensive effect of Levamlodipine and valsartan coupling and to improve albuminuretic effect better than single time spent.

Along with global aging, aged hypertensives becomes the modal disease of old section, and it has characteristics such as the course of disease is long, fluctuation of blood pressure property is big, complication is many, often need unite depressor treatment more than 2 kinds.Hypertensive renal damage is to cause the whole one of the main reasons that latter stage, renal failure increased rapidly of old people simultaneously.And urinate micro-albumin (mAlb) drainage increase is the sign of the early stage renal damage of hypertension.Merge the micro-albumin of urine with valsartan and Levamlodipine therapeutic alliance senile hypertension; Therapeutic alliance; Clinical efficacy is superior to single therapy, and has safety preferably, and two medicine Combined application can be through the effect of different mechanisms performance protecting renal function when strengthening effect of easing stress.

What wait quietly the people to valsartan associating Levamlodipine treatment essential hypertension 30 examples carried out studying (; Medicine Leader volume o. 11th in November in 2008 the 27th), inquire into valsartan and treat hypertensive antihypertensive effect with Combined application separately with Levamlodipine and reach the protective effect to renal function, reach a conclusion: valsartan, Levamlodipine is treated essential hypertension that hypotensive effect is preferably all arranged; And can reduce micro-albumin and microglobulin; Improve endogenous creatinine clearance rate, reduce the New Development renal function injury, two medicine Combined application can play synergism; More effectively bring high blood pressure down, improve early stage renal function injury index.

Levamlodipine associating valsartan treatment senile hypertension and left ventricular hypertrophy (clinical psychosomatic disease magazine the 13rd the 6th phase of volume of November in 2007) have been inquired in the Gao Xiang; Reach a conclusion: valsartan and Levamlodipine besylate all can improve left chamber diastolic function, reverse the left ventricle that enlarges; The clinical effectiveness of Levamlodipine besylate associating valsartan treatment significantly is superior to single with the Levamlodipine treatment, can be used as treatment hypertension companion left ventricular hypertrophy patient's a line medication.

The scholar of class loyalty had once been reported and had been utilized Levamlodipine besylate treatment essential hypertension; Through treatment to 40 routine outpatients, 25mg, qd oral administration; Observe the antihypertensive effect in the 2nd week and the 8th week; Effective percentage is respectively 85.0% and 95.0%, explains that the Levamlodipine antihypertensive effect is obvious and steadily, suitable essential hypertension is treated.

People such as Zhang Jun have also reported and have utilized amlodipine to treat essential hypertension; Light, moderate hypertension patient are divided into two groups immediately, carry out clinical control and test, the variation of blood pressures after observing basic blood pressure and treating for eight weeks; The result shows; Levamlodipine besylate can effectively reduce blood pressure, and effective percentage light, the moderate hypertension group is respectively 84.3% and 87.6%, explains that Levamlodipine can be used for the treatment of essential hypertension.

People such as Bi Yanzhen observe (Chinese basic unit medicine the 14th the 3rd phase of volume of March in 2007) to the curative effect of Levamlodipine and valsartan treatment diabetic nephropathy complicated hypertension; The conclusion that draws is that Levamlodipine, valsartan are treated diabetic nephropathy complicated hypertension patient separately; All can obviously bring high blood pressure down; Reduce excretion quantity of urinary protein, renal function protecting, but hypotensive effect and to improve the albuminuria effect better during two medicine couplings.

At present, drugs approved by FDA Novartis Co.,Ltd amlodipine+valsartan+hydrochlorothiazide tablet commodity compound preparation (amlodipine+valsartan+hydrochlorothiazide, Exforge HCT) listing treatment hypertension.This uses a kind of important new selection of poor effect patient after two types of antihypertensive drug therapeutic alliances to those.Existing China application CN200780024142.X (CN101478956A) discloses the solid dosage forms of a kind of valsartan, amlodipine and hydrochlorothiazide and has prepared the method for this solid dosage forms.Specifically disclose a kind of amlodipine+valsartan+hydrochlorothiazide compound recipe three-layer tablet, be included in and only contain a kind of active substance in each independent stratum.But this dosage form comes with some shortcomings, and three-layer tablet is in the preparation process, and technology is comparatively complicated, to having relatively high expectations of equipment.The preparation of three-layer tablet need be through tabletting repeatedly.In this case, may cause sheet press tension, easy disintegrating discharges; The shaping finished product rate is low relatively in the preparation, phenomenons such as sheet is more occur take, and when the survey dissolution; Three-layer tablet can not separate independent mensuration, when stripping, can receive two kinds of disintegration of tablet influences in addition.

China application CN201020197929.5 discloses a kind of compound amlodipine and valsartan hydrochlorothiazide capsule; This utility model preparation comprises capsule body 1 and loads the active agent formulation in capsule body 1; Be calcium channel blocade amlodipine sheet 2, angiotensin receptor depressant valsartan sheet 3 and diuretic hydrochlorothiazide tablet 4; Wherein amlodipine sheet 2 is made up of acceptable pharmaceutical excipient in the principal agent amlodipine benzenesulphonate of effective therapeutic dose and the pharmacy; Valsartan sheet 3 is made up of acceptable pharmaceutical excipient in the principal agent valsartan of effective therapeutic dose and the pharmacy, and hydrochlorothiazide tablet 4 is made up of acceptable pharmaceutical excipient in the principal agent hydrochlorothiazide of effective therapeutic dose and the pharmacy.Each medicine burst separates in the capsule; Amlodipine sheet 2, valsartan sheet 3 and hydrochlorothiazide tablet 4 can adopt existing, sophisticated pharmaceutical preparation respectively; Be convenient to quality control; Again can be when product inspection, tablet directly takes out from capsule, and three tablets can be tested by standard separately.When taking above-mentioned capsule, after shell capsules was melted in vivo, a capsule preparations resolved into three microplates, can discharge medicine simultaneously by drug release feature separately in vivo, can better play synergistic therapeutic effect.But the complicated process of preparation of above-mentioned compound amlodipine and valsartan hydrochlorothiazide capsule is difficult to carry out quality control effectively, and causes content of effective to reduce because each active component is processed microplate with adjuvant respectively, influences the whole curative effect of preparation.

In view of this, special proposition the present invention.

Summary of the invention

First purpose of the present invention is to provide a kind of brand-new oral administration solid medicinal compositions; The oral formulations of described Pharmaceutical composition for being prepared from acceptable auxiliary on hydrochlorothiazide, Levamlodipine, valsartan and the pharmaceutics, described oral formulations includes, but are not limited to be tablet or capsule.Levamlodipine of the present invention includes but not limited to acid group such as benzenesulfonic acid, maleic acid, L-Aspartic Acid and the crystal that forms with Levamlodipine thereof, the crystal of preferred benzenesulfonic acid and Levamlodipine formation.

Compositions of the present invention contains following raw material by weight: hydrochlorothiazide 5-25 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 80-160 weight portion, microcrystalline Cellulose 40～120 weight portions, amylum pregelatinisatum 30～90 weight portions, cross-linking sodium carboxymethyl cellulose 5～25 weight portions, silicon dioxide 3-8 weight portion and magnesium stearate 1-2 weight portion.

Preferably: hydrochlorothiazide 5-12.5 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 80 weight portions, microcrystalline Cellulose 40～60 weight portions, amylum pregelatinisatum 40～60 weight portions, cross-linking sodium carboxymethyl cellulose 5～15 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions; Or

Hydrochlorothiazide 6.25-12.5 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 100 weight portions, microcrystalline Cellulose 50～100 weight portions, amylum pregelatinisatum 30～80 weight portions, cross-linking sodium carboxymethyl cellulose 5～15 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions; Or

Hydrochlorothiazide 6.25-12.5 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 160 weight portions, microcrystalline Cellulose 70～120 weight portions, amylum pregelatinisatum 50～90 weight portions, cross-linking sodium carboxymethyl cellulose 8～20 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions.

More preferably: hydrochlorothiazide 12.5 weight portions, Levamlodipine 2.5 weight portions, valsartan 80 weight portions, microcrystalline Cellulose 50 weight portions, amylum pregelatinisatum 50 weight portions, cross-linking sodium carboxymethyl cellulose 10 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions; Or

Hydrochlorothiazide 12.5 weight portions, Levamlodipine 5 weight portions, valsartan 160 weight portions, microcrystalline Cellulose 80 weight portions, amylum pregelatinisatum 50 weight portions, cross-linking sodium carboxymethyl cellulose 10 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions.

Described hydrochlorothiazide is the hydrochlorothiazide crystal, and characteristic peak is 4.1 °, 8.2 °, 9.8 °, 12.1 °, 15.1 °, 16.7 °, 19.3 °, 20.0 °, 22.1 °, 23.3 °, 26.8 ° demonstrations at 2 θ in the X-ray powder diffraction pattern that described hydrochlorothiazide crystal use Cu-K alpha ray measures.

Described hydrochlorothiazide crystal is prepared from through following steps:

(1) hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln of hydrochlorothiazide;

(2) under agitation in acetone soln, drip distilled water, occur muddy to solution;

(3) under ultrasonic field, in step 2 gained solution, flow the organic mixed solution that adds ethanol and ether, continue to stir;

(4) continued ultrasonic 1-3 minute, leave standstill, growing the grain filters, and filter cake washs with ether, and vacuum drying gets the hydrochlorothiazide crystal.

The acetone soln concentration of hydrochlorothiazide is 0.05-0.2g/ml in the said step 1; The mixing speed of said step 2 is 80-180r/min, and the mixing speed in the said step 3 is 20-30r/min; Flow acceleration is 10-15ml/min, and the power of said ultrasonic field is 0.4～0.6KW, and the volume ratio of ethanol and ether is 2 in said organic mixed solution: 3-7: 6, and the volume ratio of said mixed liquor and acetone is 4: 5-8: 5; The growing the grain that leaves standstill of said step 4 is at 12-18 ℃ of following growing the grain 1.5-2.5 hour.

Second purpose of the present invention is to provide a kind of method for preparing of above-mentioned composition.Described compositions is a tablet, and its preparation method comprises the steps:

1) hydrochlorothiazide, valsartan and Levamlodipine are sieved respectively, subsequent use;

2) microcrystalline Cellulose, amylum pregelatinisatum, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate were dried by the fire 2～4 hours under 60～80 ℃ of conditions respectively, cross the 60-80 mesh sieve, subsequent use;

3) take by weighing above-mentioned subsequent use hydrochlorothiazide, Levamlodipine, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate by recipe quantity, adopt the equivalent method of progressively increasing to carry out mixing, obtain mixed powder;

4) take by weighing the valsartan of recipe quantity, with the resulting mixed powder mixing of step 3), obtain the pharmaceutical composition powder, sampling detects;

5) resulting pharmaceutical composition powder is carried out direct pressed powder, coating, promptly get described pharmaceutical composition.

The 3rd purpose of the present invention is to provide a kind of method for preparing of above-mentioned composition capsule, and this method for preparing comprises the steps:

3) but take by weighing above-mentioned subsequent use valsartan, Levamlodipine, microcrystalline Cellulose die mould starch, silicon dioxide, HPMC and magnesium stearate by recipe quantity; Adopt the equivalent method of progressively increasing to mix at wet mixing pelletizer, powder is uniformly mixed; Get an amount of purified water and add and carry out the wet method cutting and granulate, put that 40 ℃～50 ℃ dryings obtained particulate powder after 1 hour in the fluidized bed granulation coating machine;

4) take by weighing above-mentioned subsequent use hydrochlorothiazide by recipe quantity and adopt the equivalent method of progressively increasing to mix with step 3) resulting granules sprills, obtain the pharmaceutical composition powder, with 24 order nylon screen granulate, sampling detects;

5) resulting pharmaceutical composition powder is carried out capsule charge, promptly get described pharmaceutical composition.

Below the present invention is done further in detail to introduce:

Most of hyperpietics need more than one antihypertensive to come controlling blood pressure, and the serious hyperpietic of minority needs 3 kinds or the next strict controlling blood pressure of more medicine.Prior art discloses hydrochlorothiazide, Levamlodipine and valsartan three coupling and has treated hypertensive technical scheme; Normally adopt the tablet take two or three; Like hydrochlorothiazide valsartan compound recipe sheet+amlodipine sheet or hydrochlorothiazide tablet+amlodipine sheet+valsartan sheet, and in the actual clinical test, find that the above-mentioned mode one of taking is that dosage is big; Especially the hyperpietic is generally the old people, takes medicine all must take at least two or three and bring inconvenience to the old people at every turn; The 2nd, because every kind of tablet all contains a large amount of adjuvants, different auxiliary materials produces Different Effects to the release of active constituents of medicine, therefore, is difficult to control three kinds of active component after taking and discharges with ideal speed, influences therapeutic effect.Therefore, a kind of compound medicinal formulation that contains three components of exploitation is significant.

Drugs approved by FDA Novartis Co.,Ltd amlodipine+valsartan+hydrochlorothiazide tablet commodity compound preparation listing treatment hypertension.This uses those, and poor effect patient is a kind of important new selection after two types of antihypertensive drug therapeutic alliances.But because said preparation adjuvant content is big, and adopt the mode of dry granulation to prepare, cause the whole curative effect of preparation undesirable.In addition; Of background technology, prior art also discloses three kinds of effective ingredient has been arranged on the technical scheme in a slice or the capsule shells in every way, but finds in the actual clinical; The curative effect of above-mentioned compound preparation on resisting hypertension is still not remarkable; There is the very big space of improving, in view of this, special proposition the present invention.

The present invention puts forth effort on the compound tablet that contains hydrochlorothiazide, amlodipine and valsartan of a kind of brand-new prescription of exploitation, selects more activated Levamlodipine can obtain better therapeutic.Core more, the inventor is devoted to study selection and the consumption of this compound preparation adjuvant curative effect with further improvement above-mentioned compound preparation.

Nearest 20 years, many medicine-adjuvant Study of Interaction papers that relate to have been delivered.These researchs are intended to optimize writes out a prescription, and comprises the aspects such as dissolubility, increase dissolution, increase drug release rate, raising stability, change therapeutic activity and raising bioavailability that improve insoluble medicine.

Those skilled in the art will know that; To the body drug administration; Which kind of approaches and methods all need adopt the pharmaceutical dosage form that adapts with it, and adjuvant can be given the necessary physics of pharmaceutical dosage form or physical chemistry, biological property to adapt to medical use and to guarantee therapeutic effect.Active medicine is substantive theme part in the dosage form, is determining the whole direction of effect.Adjuvant guarantees that then medicine optionally is transported to tissue site with certain procedure, prevents that medicine from disengaging preceding inactivation from main body, and makes medicine in vivo by certain speed and time, discharge at certain position.Therefore, the dosage form of being made up of suitable adjuvant has positive pivotal role to the practical application of medicine and the performance of curative effect.Therefore the inventor is to the physicochemical property of hydrochlorothiazide, Levamlodipine and valsartan; On the basis of big quantity research and screening test, a kind of brand-new prescription has been proposed; Selected to have the adjuvant of synergy with the three and confirmed the best weight proportion of each component, to reach the purpose of final raising compound preparation curative effect.

Though what adopt in the present composition is prior art adjuvant commonly used; But those skilled in the art will know that; Contain the compound preparation of three kinds of medicinal active ingredients because the large usage quantity of principal agent contains 12.5mg hydrochlorothiazide/2.5mg Levamlodipine/80mg valsartan or 12.5mg/5mg Levamlodipine/160mg valsartan like common every of compound preparation of the present invention.For three kinds of effective ingredient can be discharged synchronously; And can reasonably discharge with rational speed in the time; Usually need to use a large amount of disintegrating agent and lubricant, it is heavy so just to have increased sheet, causes patient's difficulty of swallowing; Therefore, be the key problem that the present invention need solve how at the consumption that guarantees to reduce under the desirable prerequisite that discharges of medicine adjuvant as far as possible.The inventor is on the basis of a large amount of experiments; The combination of unexpected discovery microcrystalline Cellulose/amylum pregelatinisatum/cross-linking sodium carboxymethyl cellulose/silicon dioxide/magnesium stearate is used and can be overcome the big problem of required supplementary product consumption that exists in the prior art, and has finally confirmed following weight proportion:

Hydrochlorothiazide 5-25 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 80-160 weight portion, microcrystalline Cellulose 40～120 weight portions, amylum pregelatinisatum 30～90 weight portions, cross-linking sodium carboxymethyl cellulose 5～25 weight portions, silicon dioxide 3-8 weight portion and magnesium stearate 1-2 weight portion.

Because the present invention greatly reduces the consumption of adjuvant under the prerequisite that guarantees curative effect, therefore, it is heavy both to have reduced sheet, makes things convenient for the patient to take, the quality Control of also having avoided supplementary product consumption to bring greatly simultaneously.

The present invention can adopt commercially available hydrochlorothiazide as crude drug, but as a kind of preferred version of the present invention, the present invention can adopt a kind of hydrochlorothiazide crystal with ideal stability property and dissolution.

One skilled in the art will appreciate that stripping is slow because hydrochlorothiazide is slightly soluble in water; Had a strong impact on bioavailability of medicament, in addition, hydrochlorothiazide is owing to contain sulfonamide structure in the molecule; Less stable is easy to hydrolysis, is prone to produce the quality wild effect; Therefore, it is generally on the low side to contain the pharmaceutical preparation bioavailability of hydrochlorothiazide.Prior art mainly solves the problems referred to above through dosage form or the method for preparing that changes its pharmaceutical preparation.As preparation being made fast dissolving dosage forms such as dispersible tablet, effervescent tablet, promote its disintegrate through using a large amount of adjuvant (disintegrating agent), reach qualified dissolution.

Though adopt technique scheme can play improvement effect to a certain degree, DeGrain.And often make preparation technology become complicated, be unfavorable for controlling the quality of the pharmaceutical preparations.

Patent application CN101659643A discloses crystal form of a kind of hydrochlorothiazide and uses thereof; To the ubiquitous hydrochlorothiazide stripping of prior art slowly, the problem of bioavailability difference; Through hydrochlorothiazide is handled; Obtain a kind of new hydrochlorothiazide crystalline form iii (as shown in Figure 2), the result shows, the formulation products that the compositions of forming with hydrochlorothiazide crystalline form iii or hydrochlorothiazide III and other types depressor is processed; Its dissolution rate can reach and the external similar level of like product, has solved the slow problem of hydrochlorothiazide dissolution rate to a certain extent.But stability of formulation does not significantly improve yet, and the curative effect of pharmaceutical preparation is also undesirable.

In view of this, the inventor has obtained certain hydrochlorothiazide crystal unexpectedly after hydrochlorothiazide has carried out secular big quantity research, and this crystal efficiently solves the existing variety of issue that the hydrochlorothiazide preparation occurs that contains, and has obtained beyond thought technique effect.

As shown in Figure 1, characteristic peak is 4.1 °, 8.2 °, 9.8 °, 12.1 °, 15.1 °, 16.7 °, 19.3 °, 20.0 °, 22.1 °, 23.3 °, 26.8 ° demonstrations at 2 θ in the X-ray powder diffraction pattern that hydrochlorothiazide crystal use Cu-K alpha ray of the present invention measures.

Fig. 2 discloses the crystalline powder X-ray diffraction pattern of hydrochlorothiazide among the CN101659643A; Can know from accompanying drawing; Above-mentioned crystal is different from hydrochlorothiazide crystal of the present invention; In addition, through a large amount of control experiments of inventor, crystal of the present invention significantly is superior to the disclosed hydrochlorothiazide crystal of prior art on stability and dissolution.

The crystalline method for preparing of hydrochlorothiazide of the present invention comprises the steps:

The acetone soln concentration of hydrochlorothiazide is 0.05-0.2g/ml in the said step 1; The mixing speed of the preferred said step 2 of 0.08-0.15g/ml is 80-180r/min, preferred 120-180r/min, and the mixing speed in the said step 3 is 20-30r/min; Flow acceleration is 10-15ml/min, and the power of said ultrasonic field is 0.4～0.6KW, and the volume ratio of ethanol and ether is 2 in said organic mixed solution: 3-7: 6, and the volume ratio of said mixed liquor and acetone is 4: 5-8: 5; The growing the grain that leaves standstill of said step 4 is at 12-18 ℃ of following growing the grain 1.5-2.5 hour.

Described method for preparing comprises the steps:

(1) hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln that concentration is the 0.1g/ml hydrochlorothiazide;

(2), occur muddy to solution at the following distilled water that in acetone soln, drips of the stirring of 160r/min;

(3) power be under the ultrasonic field of 0.5KW in step 2 gained solution stream add organic mixed solution of ethanol and ether, the stirring of lasting 25r/min; The volume ratio of ethanol and ether is 5: 6 in wherein organic mixed solution, and the volume ratio of said mixed liquor and acetone is 1: 1;

(4) continue ultrasonic 2 minutes, leave standstill, 16 ℃ of following growing the grains 2 hours, filter, filter cake washs with ether, and vacuum drying gets the hydrochlorothiazide crystal.

The present invention introduces ultrasound wave control in crystalline process.Those skilled in the art will know that; Crystallization is the process of a complicacy, and each factor of crystallization process all can influence crystalline formation and control thereof like time-temperature of choice of Solvent and consumption thereof, mixing speed, growing the grain etc.; After the present invention introduces ultrasonic field and is used for crystallization; Ultransonic power and time are the crystal formation key of influence equally, and the present invention utilizes ultrasound wave to control nucleation and growth course, thereby crystallization process is optimized more.Above-mentioned method for preparing is the best method for preparing that the inventor finally confirms through a large amount of experiments back, and the hydrochlorothiazide crystal of gained possesses the remarkable result that prior art can't obtain.

Hydrochlorothiazide of the present invention is a hydrochlorothiazide powder commercially available in the prior art, the hydrochlorothiazide crystal of described hydrochlorothiazide crystal for adopting commercially available hydrochlorothiazide powder to be prepared from by method of the present invention.

In addition; The present invention also provides a kind of method for preparing of above-mentioned solid pharmaceutical composition tablet; One skilled in the art will appreciate that compound tablet compositions of the present invention is scientific and reasonable owing to what write out a prescription, therefore can predict and adopt disclosed other method for preparing tablet thereof of prior art also can obtain eutherapeutic tablet composition; Preferred but the method for preparing that is not limited only to be described below of the present invention, this method for preparing comprises the steps:

The inventor has confirmed the method for preparing of above-mentioned tablet composition to the characteristic of main ingredient, is to simplify production process, keeps the activity of ingredient as far as possible, and the present invention adopts direct pressure closing to prepare compound tablet.The reasonable release that to control hydrochlorothiazide, valsartan and Levamlodipine that is used in combination owing to microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate; And adopt direct pressure closing to help the rapid release of medicine; Therefore, Pharmaceutical composition of the present invention can obtain better therapeutic effect than prior art formulations.Wherein, the method for a kind of mixed material medicine that the equivalent of the present invention method of progressively increasing is used always for those skilled in the art, concrete operations are familiar with by those skilled in the art and are grasped.

The 3rd purpose of the present invention is to provide a kind of method for preparing of above-mentioned composition capsule; Those skilled in the art will know that; Compound preparation of the present invention is owing to prescription is scientific and reasonable; Therefore can predict and adopt disclosed other capsule preparation method thereofs of prior art also can obtain eutherapeutic capsule compositions, the preferred but method for preparing that is not limited only to be described below of the present invention, this method for preparing comprises the steps:

Wherein, the method for a kind of mixed material medicine that the equivalent method of progressively increasing is used always for those skilled in the art, concrete operations are familiar with by those skilled in the art and are grasped.The consumption of purified water is as the criterion can mixed powder being carried out wet method cutting granulation in the step 3, and concrete consumption is to be determined on a case-by-case basis in the practical operation, and this selection and judgement are also grasped by those skilled in the art.

Adopt technique scheme: the present invention has following beneficial effect:

1, the medicinal compositions drug content of oral administration solid of the present invention is high, and supplementary product consumption is merely the 1/5-1/3 of prior art.

2, the present invention adopt with 3 kinds of medicines be combined in 11 time on the one, this compound tablet is taken more convenient, helps to control better patient's blood pressure.

3, the present invention writes out a prescription rationally, and bioavailability significantly improves, than all 2 above same dose medication combined use reduction systolic pressures 24%～43% and diastolic pressure 18%～45% more.

Description of drawings

Fig. 1 hydrochlorothiazide crystal powder of the present invention diffraction pattern

The disclosed hydrochlorothiazide crystalline form iii of Fig. 2 CN101659643A powder diagram

The specific embodiment

Following embodiment will do to explain more specifically to the present invention, but the present invention is not limited only to these embodiment, and these embodiment do not limit the present invention in any way yet equally.

The crystalline preparation of embodiment 1 hydrochlorothiazide

(1) the 1kg hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln that concentration is the 0.1g/ml hydrochlorothiazide;

As shown in Figure 1, characteristic peak is 4.1 °, 8.2 °, 9.8 °, 12.1 °, 15.1 °, 16.7 °, 19.3 °, 20.0 °, 22.1 °, 23.3 °, 26.8 ° demonstrations at 2 θ in the X-ray powder diffraction pattern that present embodiment gained hydrochlorothiazide crystal use Cu-K alpha ray measures.

The crystalline preparation of embodiment 2 hydrochlorothiazide

(1) the 1kg hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln that concentration is the 0.2g/ml hydrochlorothiazide;

(2), occur muddy to solution at the following distilled water that in acetone soln, drips of the stirring of 120r/min;

(3) power be under the ultrasonic field of 0.4KW in step 2 gained solution stream add organic mixed solution of ethanol and ether, the stirring of lasting 20r/min; The volume ratio of ethanol and ether is 2: 3 in wherein organic mixed solution, and the volume ratio of said mixed liquor and acetone is 4: 5;

(4) continue ultrasonic 2 minutes, leave standstill, 12 ℃ of following growing the grains 1.5 hours, filter, filter cake washs with ether, and vacuum drying gets the hydrochlorothiazide crystal.

The crystalline preparation of embodiment 3 hydrochlorothiazide

(1) the 1kg hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln that concentration is the 0.08g/ml hydrochlorothiazide;

(2), occur muddy to solution at the following distilled water that in acetone soln, drips of the stirring of 180r/min;

(3) power be under the ultrasonic field of 0.6KW in step 2 gained solution stream add organic mixed solution of ethanol and ether, the stirring of lasting 30r/min; The volume ratio of ethanol and ether is 7: 6 in wherein organic mixed solution, and the volume ratio of said mixed liquor and acetone is 8: 5;

(4) continue ultrasonic 3 minutes, leave standstill, 18 ℃ of following growing the grains 2.5 hours, filter, filter cake washs with ether, and vacuum drying gets the hydrochlorothiazide crystal.

The crystalline preparation of embodiment 4 hydrochlorothiazide

(1) the 1kg hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln that concentration is the 0.05g/ml hydrochlorothiazide;

(2), occur muddy to solution at the following distilled water that in acetone soln, drips of the stirring of 130r/min;

(3) power be under the ultrasonic field of 0.55KW in step 2 gained solution stream add organic mixed solution of ethanol and ether, the stirring of lasting 20r/min; The volume ratio of ethanol and ether is 1: 1 in wherein organic mixed solution, and the volume ratio of said mixed liquor and acetone is 6: 5;

(4) continue ultrasonic 1.5 minutes, leave standstill, 12 ℃ of following growing the grains 1.5 hours, filter, filter cake washs with ether, and vacuum drying gets the hydrochlorothiazide crystal.

The crystalline preparation of embodiment 5 hydrochlorothiazide

(1) hydrochlorothiazide is dissolved in the acetone, obtains the acetone soln that concentration is the 0.15g/ml hydrochlorothiazide;

(2), occur muddy to solution at the following distilled water that in acetone soln, drips of the stirring of 80r/min;

(3) power be under the ultrasonic field of 0.45KW in step 2 gained solution stream add organic mixed solution of ethanol and ether, the stirring of lasting 20r/min; The volume ratio of ethanol and ether is 5: 6 in wherein organic mixed solution, and the volume ratio of said mixed liquor and acetone is 5: 4;

(4) continue ultrasonic 3 minutes, leave standstill, 18 ℃ of following growing the grains 2 hours, filter, filter cake washs with ether, and vacuum drying gets the hydrochlorothiazide crystal.

The preparation of embodiment 6 tablets

Prescription: (processing 1000)

Hydrochlorothiazide 12.5g, Levamlodipine besylate 5g, valsartan 160g, microcrystalline Cellulose 80g, amylum pregelatinisatum 50g, cross-linking sodium carboxymethyl cellulose 10g, silicon dioxide 5g and magnesium stearate 1.5g.Wherein, the described hydrochlorothiazide of present embodiment is the prepared hydrochlorothiazide crystal of embodiment 2.

Method for preparing:

1) hydrochlorothiazide, valsartan and Levamlodipine besylate are sieved respectively, subsequent use;

2) microcrystalline Cellulose, amylum pregelatinisatum, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate were dried by the fire 3 hours under 70 ℃ of conditions respectively, cross 70 mesh sieves, subsequent use;

3) take by weighing above-mentioned subsequent use hydrochlorothiazide, Levamlodipine besylate, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate by recipe quantity, adopt the equivalent method of progressively increasing to carry out mixing, obtain mixed powder;

The preparation of embodiment 7 tablets

Prescription: (processing 1000)

Hydrochlorothiazide 12.5g, Levamlodipine besylate 2.5g, valsartan 80g, microcrystalline Cellulose 50g, amylum pregelatinisatum 50g, cross-linking sodium carboxymethyl cellulose 10g, silicon dioxide 5g and magnesium stearate 1.5g.Wherein, the described hydrochlorothiazide of present embodiment is the prepared hydrochlorothiazide crystal of embodiment 1.

Method for preparing:

2) microcrystalline Cellulose, amylum pregelatinisatum, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate were dried by the fire 4 hours under 60 ℃ of conditions respectively, cross 60 mesh sieves, subsequent use;

The preparation of embodiment 8 tablets

Prescription: (processing 1000)

Hydrochlorothiazide 6.25g, Levamlodipine besylate 2.5g, valsartan 160g, microcrystalline Cellulose 70g, amylum pregelatinisatum 90g, cross-linking sodium carboxymethyl cellulose 20g, silicon dioxide 5g and magnesium stearate 1.5g.

Method for preparing:

2) microcrystalline Cellulose, amylum pregelatinisatum, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate were dried by the fire 2 hours under 80 ℃ of conditions respectively, cross 80 mesh sieves, subsequent use;

The preparation of embodiment 9 tablets

Compare with embodiment 6, distinctive points only is that the present embodiment prescription is:

Hydrochlorothiazide 12.5g, maleic acid levo amido chloro diping 5g, valsartan 160g, microcrystalline Cellulose 120g, amylum pregelatinisatum 50g, cross-linking sodium carboxymethyl cellulose 8g, silicon dioxide 5g and magnesium stearate 1.5g.

The preparation of embodiment 10 tablets

Hydrochlorothiazide 6.25g, L-Aspartic Acid Levamlodipine 2.5g, valsartan 100g, microcrystalline Cellulose 50g, amylum pregelatinisatum 80g, cross-linking sodium carboxymethyl cellulose 5g, silicon dioxide 5g and magnesium stearate 1.5g.

Embodiment 11 capsular preparations

Prescription:

Hydrochlorothiazide 12.5g, Levamlodipine besylate 5g, valsartan 100g, microcrystalline Cellulose 100g, amylum pregelatinisatum 30g, cross-linking sodium carboxymethyl cellulose 15g, silicon dioxide 5g and magnesium stearate 1.5g.Wherein, hydrochlorothiazide is the hydrochlorothiazide crystal of embodiment 1 gained in this instance.

Method for preparing:

3) but take by weighing above-mentioned subsequent use valsartan, Levamlodipine, microcrystalline Cellulose die mould starch, silicon dioxide, HPMC and magnesium stearate by recipe quantity; Adopt the equivalent method of progressively increasing to mix at wet mixing pelletizer, powder is uniformly mixed; Get an amount of purified water and add and carry out the wet method cutting and granulate, put that 45 ℃ of dryings obtained particulate powder after 1 hour in the fluidized bed granulation coating machine;

Embodiment 12 capsular preparations

Prescription: (processing 1000)

Hydrochlorothiazide 5g, Levamlodipine besylate 2.5g, valsartan 80g, microcrystalline Cellulose 40g, amylum pregelatinisatum 60g, cross-linking sodium carboxymethyl cellulose 5g, silicon dioxide 5g and magnesium stearate 1.5g.Wherein, the described hydrochlorothiazide of present embodiment is the prepared hydrochlorothiazide crystal of embodiment 2.

Method for preparing:

2) microcrystalline Cellulose, amylum pregelatinisatum, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate were dried by the fire 2 hours under 80 ℃ of conditions respectively, cross 60 mesh sieves, subsequent use;

3) but take by weighing above-mentioned subsequent use valsartan, Levamlodipine, microcrystalline Cellulose die mould starch, silicon dioxide, HPMC and magnesium stearate by recipe quantity; Adopt the equivalent method of progressively increasing to mix at wet mixing pelletizer, powder is uniformly mixed; Get an amount of purified water and add and carry out the wet method cutting and granulate, put that 40 ℃ of dryings obtained particulate powder after 1 hour in the fluidized bed granulation coating machine;

Embodiment 13 capsular preparations

Prescription: (processing 1000)

Hydrochlorothiazide 12.5g, Levamlodipine besylate 5g, valsartan 80g, microcrystalline Cellulose 60g, amylum pregelatinisatum 40g, cross-linking sodium carboxymethyl cellulose 15g, silicon dioxide 5g and magnesium stearate 1.5g.Wherein, the described hydrochlorothiazide of present embodiment is the prepared hydrochlorothiazide crystal of embodiment 2.

Method for preparing:

2) microcrystalline Cellulose, amylum pregelatinisatum, cross-linking sodium carboxymethyl cellulose, silicon dioxide and magnesium stearate were dried by the fire 4 hours under 60 ℃ of conditions respectively, cross 80 mesh sieves, subsequent use;

3) but take by weighing above-mentioned subsequent use valsartan, Levamlodipine, microcrystalline Cellulose die mould starch, silicon dioxide, HPMC and magnesium stearate by recipe quantity; Adopt the equivalent method of progressively increasing to mix at wet mixing pelletizer, powder is uniformly mixed; Get an amount of purified water and add and carry out the wet method cutting and granulate, put that 50 ℃ of dryings obtained particulate powder after 1 hour in the fluidized bed granulation coating machine;

Embodiment 14 capsular preparations

Compare with embodiment 11, distinctive points only is that the present embodiment prescription is:

Hydrochlorothiazide 5g, maleic acid levo amido chloro diping 2.5g, valsartan 80g, microcrystalline Cellulose 120g, amylum pregelatinisatum 30g, cross-linking sodium carboxymethyl cellulose 5g, silicon dioxide 3g and magnesium stearate 1g.

Embodiment 15 capsular preparations

Compare with embodiment 12, distinctive points only is that the present embodiment prescription is:

Hydrochlorothiazide 25g, L-Aspartic Acid Levamlodipine 5g, valsartan 160g, microcrystalline Cellulose 40g, amylum pregelatinisatum 90g, cross-linking sodium carboxymethyl cellulose 25g, silicon dioxide 8g and magnesium stearate 2g.Wherein, the described hydrochlorothiazide of present embodiment is the prepared hydrochlorothiazide crystal of embodiment 2.

In order further to verify stability, safety and the curative effect thereof of the medicinal composite preparation of oral administration solid that the present invention protected, the inventor has done a series of development test to the present invention, and is specific as follows:

Test Example 1 dissolution is investigated

The dissolution with the different tablets of dosage has been investigated in this test.

Experimental group 1: the embodiment of the invention 7, wherein the hydrochlorothiazide crystal is embodiment 1 a gained hydrochlorothiazide crystal;

Experimental group 2: compare with the embodiment of the invention 7, distinctive points only is: the principal agent in the prescription adopts disclosed hydrochlorothiazide crystalline form iii among the CN101659643A;

Experimental group 3: the embodiment of the invention 7; Wherein the hydrochlorothiazide crystal is the commercially available hydrochlorothiazide of prior art;

Experimental group 4: drugs approved by FDA Novartis Co.,Ltd amlodipine+valsartan+hydrochlorothiazide tablet commodity compound preparation (amlodipine+valsartan+hydrochlorothiazide, Exforge HCT); Every contains valsartan 80mg, hydrochlorothiazide 12.5mg and Levamlodipine 5mg.

Experimental group 5: hydrochlorothiazide/valsartan sheet+Levamlodipine beaylate tablets;

Experimental group 6: hydrochlorothiazide tablet+Levamlodipine beaylate tablets+valsartan sheet.

Wherein, Hydrochlorothiazide tablet in the experimental group 5,6 is selected from Shanxi Heng Ruida pharmaceutical Co. Ltd (containing hydrochlorothiazide 12.5mg); Levamlodipine beaylate tablets is selected from Zhejiang Anglikang Pharmaceutical Co., Ltd.'s (containing Levamlodipine besylate 5mg); The valsartan sheet is selected from Novartis Pharma AG's (containing valsartan 80mg), and hydrochlorothiazide/valsartan sheet is selected from Zhejiang Yinggelai Pharmaceutical Co., Ltd, (containing valsartan 80mg and hydrochlorothiazide 12.5mg).A, B, C represent hydrochlorothiazide, Levamlodipine besylate and valsartan respectively.

Test method:

According to 2005 editions two appendix dissolution determination first methods of Chinese Pharmacopoeia; With 0.05M; The PBS 1000ml of pH6.8 is as dissolution medium; Rotating speed is 50rmp, measures the dissolution of respectively organizing principal agent composition in the tablet at 0.5min, 0.8min, 1min, 2min, 5min, 8min, 10min, 15min, 20min respectively, and concrete experimental implementation is grasped by those skilled in the art.

The result sees table 1:

Table 1

The result shows: the compound preparation that the present invention requires to protect has good dissolution; In entire test, can continue to realize discharging synchronously; Experimental group 1 is compared with experimental group 2,3, adopts identical consumption and method for preparing, and distinctive points only is that experimental group 1 adopts the hydrochlorothiazide crystal of the present invention's preparation; And experimental group 2 adopts disclosed hydrochlorothiazide crystalline form iii among the CN101659643A; Experimental group 3 adopts commercially available hydrochlorothiazide, and experimental group 2,3 also all can be realized synchronous release preferably, but the dissolution of hydrochlorothiazide is lower; In addition, experimental group 1-3 compares with experimental group 4-6, has not only realized synchronous release, and has significantly improved dissolution, therefore more can improve medicine in the intravital absorption of people, helps to improve the preparation curative effect.This is the beneficial effect that prior art can't obtain.

Other embodiment is carried out same experiment, draw identical conclusion.

Test Example 2 study on the stability

Test method:

Method: 30 ± 2 ℃ of temperature, the condition held of relative humidity 60 ± 5% 3 months, each sampling in the 1st, 2,3 month that tests once; Measure drug content respectively, check catabolite, and observe the appearance character of tablet with HPLC; With result's contrast in 0 month, the result saw table 2.

Table 2: hydrochlorothiazide/Levamlodipine/valsartan tablet composition study on the stability

The result shows: after quickening 3 months study on the stability, the drug content of experimental group 1-3 is all significantly stable than experimental group 4-6.Explanation has ideal stability according to the compound preparation of prescription of the present invention and method for preparing gained; Wherein, The stability of hydrochlorothiazide component is best with experimental group 1, explains and adopts hydrochlorothiazide crystal of the present invention more to help the stability that provides compound preparation whole.Other embodiment is carried out same experiment, all draw identical conclusion.

Test Example 3 pharmacodynamic experiments

One, data and method

1, case is selected " internal medicine " 2006 editions diagnostic criterias about " essential hypertension " with reference to the Wang Jiyao chief editor; Do not take under the antihypertensive drug situation systolic pressure >=140mgHg with (or) diastolic pressure >=90mgHg; Picked at random hyperpietic's 240 examples; The patient is divided into experimental group 1-6 at random, every group 40 example, each is organized those selected general clinical setting and sees table 3:

Table 3: each organizes hyperpietic's general clinical setting

2, research method

All patients inactive blood pressure lowering and other vasoactive agents in 2 weeks before test.According to different groups, the patient takes different antihypertensive drugs, and each organizes all in the morning 6 to 8 o'clock patient medicine time, and be 8 weeks the course of treatment.

3, follow-up method 1 week before treatment, 2 weeks of taking medicine, 4 weeks, 6 weeks, 8 weeks are the blood pressure situation of measuring patient respectively, adds up to and follows up a case by regular visits to 5 times, and the instrument of blood pressure measurement and method all adopt prior art to use always, and this those skilled in the art of being measured as grasp.

4, drug safety evaluation

The patient all need carry out the drug safety evaluation, comprising the generation and the lab index (routine blood test and biochemical analysis) of untoward reaction incident in acceptance is followed up a case by regular visits at every turn.

5, experimental result: see table 4, table 5.

Table 4:8 respectively organizes the hyperpietic after week therapeutic effect compares

Table 5:8 respectively organizes hyperpietic's adverse effect situation after week

The above results shows: after 8 weeks; The compound preparation of experimental group 1-3 significantly is superior to experimental group 4-6 in the reduction effect to systolic pressure and diastolic pressure; In addition, in 1 week before treatment, 2 weeks of back of taking medicine, 4 weeks, 6 weeks, 8 weeks are the blood pressure situation of measuring patient respectively; Find that systolic pressure and the diastolic pressure of experimental group 1 in each stage all is lower than experimental group 2-5, the antihypertensive effect of visible experimental group 1 is the most desirable.In addition; From the untoward reaction incident in view of a situation arises; The untoward reaction of experimental group 1-3 significantly is less than experimental group 4-6, and wherein experimental group 1 number that untoward reaction occurs only accounts for 7.5%, far below 47.5% of experimental group 6; It is thus clear that the compound preparation that the present invention requires to protect is safe, suitablely apply clinically.

In addition, other embodiment of the present invention are done above-mentioned test, all can draw same conclusions, because length is limit, give an example no longer one by one here.

Claims

1. medicinal compositions of brand-new oral administration solid; It is characterized in that; The oral formulations of described Pharmaceutical composition for being prepared from acceptable auxiliary on hydrochlorothiazide, Levamlodipine, valsartan and the pharmaceutics, described oral formulations includes, but are not limited to be tablet or capsule.

2. Pharmaceutical composition according to claim 1; It is characterized in that: described Levamlodipine includes but not limited to acid group such as benzenesulfonic acid, maleic acid, L-Aspartic Acid and the crystal that forms with Levamlodipine thereof, the crystal of preferred benzenesulfonic acid and Levamlodipine formation.

3. Pharmaceutical composition according to claim 1 and 2; It is characterized in that: described compositions contains following raw material by weight: hydrochlorothiazide 5-25 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 80-160 weight portion, microcrystalline Cellulose 40～120 weight portions, amylum pregelatinisatum 30～90 weight portions, cross-linking sodium carboxymethyl cellulose 5～25 weight portions, silicon dioxide 3-8 weight portion and magnesium stearate 1-2 weight portion.

4. Pharmaceutical composition according to claim 3 is characterized in that: described compositions contains following raw material by weight:

Hydrochlorothiazide 5-12.5 weight portion, Levamlodipine 2.5-5 weight portion, valsartan 80 weight portions, microcrystalline Cellulose 40～60 weight portions, amylum pregelatinisatum 40～60 weight portions, cross-linking sodium carboxymethyl cellulose 5～15 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions; Or

5. Pharmaceutical composition according to claim 4 is characterized in that: described compositions contains following raw material by weight:

Hydrochlorothiazide 12.5 weight portions, Levamlodipine 2.5 weight portions, valsartan 80 weight portions, microcrystalline Cellulose 50 weight portions, amylum pregelatinisatum 50 weight portions, cross-linking sodium carboxymethyl cellulose 10 weight portions, silicon dioxide 5 weight portions and magnesium stearate 1.5 weight portions; Or

6. Pharmaceutical composition according to claim 1; It is characterized in that: described hydrochlorothiazide is the hydrochlorothiazide crystal, and characteristic peak is 4.1 °, 8.2 °, 9.8 °, 12.1 °, 15.1 °, 16.7 °, 19.3 °, 20.0 °, 22.1 °, 23.3 °, 26.8 ° demonstrations at 2 θ in the X-ray powder diffraction pattern that described hydrochlorothiazide crystal use Cu-K alpha ray measures.

7. Pharmaceutical composition according to claim 6 is characterized in that: described hydrochlorothiazide crystal is prepared from through following steps:

8. Pharmaceutical composition according to claim 7 is characterized in that: the acetone soln concentration of hydrochlorothiazide is 0.05-0.2g/ml in the said step 1; The mixing speed of said step 2 is 80-180r/min, and the mixing speed in the said step 3 is 20-30r/min; Flow acceleration is 10-15ml/min, and the power of said ultrasonic field is 0.4～0.6KW, and the volume ratio of ethanol and ether is 2 in said organic mixed solution: 3-7: 6, and the volume ratio of said mixed liquor and acetone is 4: 5-8: 5; The growing the grain that leaves standstill of said step 4 is at 12-18 ℃ of following growing the grain 1.5-2.5 hour.

9. the method for preparing of the said Pharmaceutical composition of claim 1, it is characterized in that: described compositions is a tablet, and its preparation method comprises the steps:

10. the method for preparing of the said Pharmaceutical composition of claim 1 is characterized in that, described compositions is a capsule, and its preparation method comprises the steps: